Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
🩺 Protocol Summary
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
Primary Research Facility: Princess Margaret Cancer Centre (Toronto, Ontario)
📋 Basic Study Criteria & Logistics Checklist
0 of 3 CheckedReview these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).
📍 Primary Site Map
Site: Princess Margaret Cancer Centre — Toronto, Ontario
📍 All Participating Trial Locations (3 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.